{"id":"W2129508275","doi":"10.14694/edbook_am.2015.35.e41","title":"Neoadjuvant and Adjuvant Therapy for HER2 Positive Disease","year":2015,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Clinical trial; Disease; Chemotherapy; Adjuvant; Metastatic breast cancer; Pertuzumab; Adjuvant therapy; Cancer; Targeted therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002739219,0.0005791277,0.0008607493,0.001312266,0.0001509569,0.0003795302,0.0004760727,0.0004694365,0.003092134],"category_scores_gemma":[0.0004761254,0.0001663605,0.0003656243,0.001320911,0.0002651221,0.0005690685,0.0004225491,0.001368646,0.001829611],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003480862,"about_ca_system_score_gemma":0.0004501145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007129228,"about_ca_topic_score_gemma":0.002148804,"domain_scores_codex":[0.999896,0.00002057267,0.00001400106,0.00001883589,0.00004212367,0.000008492292],"domain_scores_gemma":[0.9998871,0.00005217784,0.00002371137,0.000003969702,0.00002236155,0.00001055404],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007524156,0.00005198462,0.0001187558,0.009062814,0.00006251042,0.0001157186,0.0000241023,0.0002140985,0.0009264262,0.001080545,0.04486355,0.9434043],"study_design_scores_gemma":[0.00004129437,0.0001262123,0.001415443,0.004760693,0.00009948419,0.002184541,0.00003055424,0.00008172349,0.0003868119,0.001248357,0.9896102,0.00001478736],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009326173,0.998764,0.00005630738,0.0001451301,0.0002186012,0.000003471494,0.00001398442,0.000004361947,0.0007007843],"genre_scores_gemma":[0.0008142173,0.9975701,0.0001102713,0.0003637046,0.0002341884,0.00000634999,0.00004095397,0.000001418721,0.0008589029],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003092134,"threshold_uncertainty_score":0.01034427,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3077707158593259,"score_gpt":0.6224921145437846,"score_spread":0.3147213986844588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}